COSMO PHARMACEUTICALS NV (C43.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:C43 • NL0011832936
C43.DE Key Statistics, Chart & Performance
The current stock price of C43.DE is 48.8 EUR. In the past month the price decreased by -17.98%. In the past year, price decreased by -32.22%.
C43.DE Technical Analysis
C43.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 9 / 10 to C43.DE. C43.DE scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
C43.DE Financial Highlights
Over the last trailing twelve months C43.DE reported a non-GAAP Earnings per Share(EPS) of 8.16. The EPS increased by 1315.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 49.94% | ||
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| Debt/Equity | 0 |
C43.DE Forecast & Estimates
10 analysts have analysed C43.DE and the average price target is 104.72 EUR. This implies a price increase of 114.58% is expected in the next year compared to the current price of 48.8.
For the next year, analysts expect an EPS growth of -23.67% and a revenue growth -19.4% for C43.DE
C43.DE Ownership
About C43.DE
Company Profile
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. The company is headquartered in Dublin, Dublin and currently employs 322 full-time employees. The company went IPO on 2016-05-18. The firm is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Breezula (clascoterone), GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, CB-01-33 (colesevelam), and CB-01-35. The firm's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travelers’ diarrhea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Company Info
COSMO PHARMACEUTICALS NV
Riverside II, Sir John Rogerson's Quay
DUBLIN DUBLIN IE
Employees: 322
Phone: 35318170370
COSMO PHARMACEUTICALS NV / C43.DE FAQ
What does C43 do?
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. The company is headquartered in Dublin, Dublin and currently employs 322 full-time employees. The company went IPO on 2016-05-18. The firm is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Breezula (clascoterone), GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, CB-01-33 (colesevelam), and CB-01-35. The firm's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travelers’ diarrhea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
What is the current price of C43 stock?
The current stock price of C43.DE is 48.8 EUR. The price decreased by -2.4% in the last trading session.
Does C43 stock pay dividends?
COSMO PHARMACEUTICALS NV (C43.DE) has a dividend yield of 3.85%. The yearly dividend amount is currently 2.
How is the ChartMill rating for COSMO PHARMACEUTICALS NV?
C43.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 9 out of 10.
Should I buy C43 stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on C43.DE.
Can you provide the number of employees for COSMO PHARMACEUTICALS NV?
COSMO PHARMACEUTICALS NV (C43.DE) currently has 322 employees.
What is the market capitalization of C43 stock?
COSMO PHARMACEUTICALS NV (C43.DE) has a market capitalization of 855.95M EUR. This makes C43.DE a Small Cap stock.